234 related articles for article (PubMed ID: 31735756)
1. [Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice].
Matsukawa Y; Funahashi Y; Gotoh M
Nihon Yakurigaku Zasshi; 2019; 154(5):265-269. PubMed ID: 31735756
[TBL] [Abstract][Full Text] [Related]
2. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
[TBL] [Abstract][Full Text] [Related]
3. Effect of systemic atherosclerosis on overactive bladder symptoms in men with benign prostatic hyperplasia.
Lee D; Koo KC; Yoo JW; Lee KS
Low Urin Tract Symptoms; 2022 Jan; 14(1):35-40. PubMed ID: 34323012
[TBL] [Abstract][Full Text] [Related]
4. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
5. Lower Urinary Tract Symptoms: What's New in Medical Treatment?
Peyronnet B; Brucker BM; Michel MC
Eur Urol Focus; 2018 Jan; 4(1):17-24. PubMed ID: 29665997
[TBL] [Abstract][Full Text] [Related]
6. [Benign Prostate Hyperplasia - Current Medical Therapy, New Developments, and Side Effects].
Tamalunas A; Keller P; Schott M; Atzler M; Ebner B; Hennenberg M; Stief CG; Magistro G
Ther Umsch; 2023 Apr; 80(3):113-122. PubMed ID: 36975030
[TBL] [Abstract][Full Text] [Related]
7. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
Verheggen BG; Lee R; Lieuw On MM; Treur MJ; Botteman MF; Kaplan SA; Trocio JN
J Med Econ; 2012; 15(3):586-600. PubMed ID: 22332704
[TBL] [Abstract][Full Text] [Related]
8. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
Matsuo T; Miyata Y; Kakoki K; Yuzuriha M; Asai A; Ohba K; Sakai H
BMC Urol; 2016 Jul; 16(1):45. PubMed ID: 27473059
[TBL] [Abstract][Full Text] [Related]
10. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
11. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron for male lower urinary tract symptoms.
Suarez O; Osborn D; Kaufman M; Reynolds WS; Dmochowski R
Curr Urol Rep; 2013 Dec; 14(6):580-4. PubMed ID: 23913200
[TBL] [Abstract][Full Text] [Related]
13. Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?
Cornu JN; Grise P
Curr Opin Urol; 2016 Jan; 26(1):17-21. PubMed ID: 26574877
[TBL] [Abstract][Full Text] [Related]
14. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
15. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
[TBL] [Abstract][Full Text] [Related]
16. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
[TBL] [Abstract][Full Text] [Related]
17. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
18. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
De Nunzio C; Presicce F; Tubaro A
Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
[TBL] [Abstract][Full Text] [Related]
19. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
20. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
